DRUGapproved
Cisplatin
Mechanism
Standard 1st-line chemo for CCA (with gemcitabine).
Related claims (50)
| Type | Predicate | Conf | Source |
|---|---|---|---|
| drug efficacy | (observed in patient cohort) The objective response rate was 31.1% among 45 patients with advanced biliary tree cancer treated with durvalumab plus cisplatin and gemcitabine as first-line treatment. | 100% | 39566070 |
| survival | (observed in patient cohort) The median overall survival was 15.8 months among patients with advanced biliary tree cancer treated with durvalumab plus cisplatin and gemcitabine as first-line treatment. | 100% | 39566070 |
| drug efficacy | (observed in patient cohort) The objective response rate was 31.1% among 45 patients with advanced biliary tree cancer treated with durvalumab plus cisplatin and gemcitabine as first-line treatment. | 100% | 39566070 |
| survival | (observed in patient cohort) The median progression-free survival was 5.6 months in patients with advanced biliary tree cancer treated with durvalumab plus cisplatin and gemcitabine as first-line treatment. | 100% | 39566070 |
| survival | (observed in patient cohort) The median overall survival was 15.8 months (95%CI, 7.9-23.8) in patients with advanced biliary tree cancer treated with durvalumab plus cisplatin and gemcitabine as first-line treatment. | 100% | 39566070 |
| survival | (clinical trial result) Durvalumab plus first-line chemotherapy (gemcitabine plus cisplatin) showed improved survival vs chemotherapy alone in the TOPAZ-1 trial. | 100% | 39566070 |
| survival | (observed in patient cohort) The median overall survival was 15.8 months in patients with advanced biliary tree cancer treated with durvalumab plus cisplatin and gemcitabine as first-line treatment. | 100% | 39566070 |
| drug efficacy | (observed in patient cohort) The objective response rate was 31.1% among 45 patients with advanced biliary tree cancer treated with durvalumab plus cisplatin and gemcitabine as first-line treatment. | 100% | 39566070 |
| survival | (clinical trial result) Durvalumab plus first-line chemotherapy (gemcitabine plus cisplatin) showed improved survival vs chemotherapy alone in the TOPAZ-1 trial. | 100% | 39566070 |
| survival | (observed in patient cohort) The median progression-free survival was 5.6 months (95%CI, 4.4-6.9) in patients with advanced biliary tree cancer treated with durvalumab plus cisplatin and gemcitabine as first-line treatment. | 100% | 39566070 |
| survival | (clinical trial result) Durvalumab plus first-line chemotherapy (gemcitabine plus cisplatin) showed improved survival vs chemotherapy alone in the TOPAZ-1 trial. | 100% | 39566070 |
| survival | (clinical trial result) Durvalumab plus first-line chemotherapy (gemcitabine plus cisplatin) showed improved survival vs chemotherapy alone in the TOPAZ-1 trial. | 100% | 39566070 |
| drug efficacy | Pembrolizumab in combination with cisplatin and gemcitabine is approved for the treatment of patients with unresectable or metastatic biliary tract cancers (BTC) (clinical trial result). | 100% | 38856639 |
| survival | (observed in patient cohort) Responders to durvalumab plus cisplatin and gemcitabine had significantly longer survival than non-responders (15.8 vs 3.3 months). | 100% | 39566070 |
| survival | (observed in patient cohort) Responders to durvalumab plus cisplatin and gemcitabine had significantly longer survival than non-responders (15.8 vs 3.3 months). | 100% | 39566070 |
| survival | (observed in patient cohort) The median overall survival was 15.8 months in patients with advanced biliary tree cancer treated with durvalumab plus cisplatin and gemcitabine as first-line treatment. | 100% | 39566070 |
| drug efficacy | Treatment with gemcitabine+cisplatin+durvalumab(GCD) resulted in a complete response in a patient with intrahepatic cholangiocarcinoma with lymph node recurrence (clinical trial result). | 100% | 40420374 |
| drug efficacy | Durvalumab in combination with cisplatin and gemcitabine is approved for the treatment of patients with unresectable or metastatic biliary tract cancers (BTC) (clinical trial result). | 100% | 38856639 |
| drug efficacy | Durvalumab is approved for adults with advanced biliary tract cancer in combination with gemcitabine and cisplatin. | 100% | 37943483 |
| survival | (clinical trial result) Durvalumab plus first-line chemotherapy (gemcitabine plus cisplatin) showed improved survival vs chemotherapy alone in the TOPAZ-1 trial. | 100% | 39566070 |
| drug efficacy | (observed in patient cohort) Among 45 patients with advanced biliary tree cancer treated with durvalumab plus cisplatin and gemcitabine as first-line treatment, the objective response rate was 31.1%. | 100% | 39566070 |
| survival | (clinical trial result) Durvalumab plus first-line chemotherapy (gemcitabine plus cisplatin) showed improved survival vs chemotherapy alone in the TOPAZ-1 trial. | 100% | 39566070 |
| drug efficacy | (observed in patient cohort) Among the 45 patients with advanced biliary tree cancer treated with durvalumab plus cisplatin and gemcitabine as first-line treatment, the objective response rate was 31.1% (14 partial responses). | 100% | 39566070 |
| drug efficacy | Pembrolizumab in combination with cisplatin and gemcitabine is approved for the treatment of patients with unresectable or metastatic biliary tract cancers (BTC) (clinical trial result). | 100% | 38856639 |
| survival | Durvalumab in combination with gemcitabine and cisplatin (GCD) treatment showed a survival benefit in patients with advanced biliary tract cancer (clinical trial result). | 100% | 40868170 |
| survival | (observed in patient cohort) The median overall survival was 15.8 months (95%CI, 7.9-23.8) in patients with advanced biliary tree cancer treated with durvalumab plus cisplatin and gemcitabine as first-line treatment. | 100% | 39566070 |
| drug efficacy | Durvalumab, in combination with gemcitabine and cisplatin, has received FDA approval for treatment of advanced BTC. | 100% | 38774819 |
| survival | (observed in patient cohort) The median progression-free survival was 5.6 months (95%CI, 4.4-6.9) in patients with advanced biliary tree cancer treated with durvalumab plus cisplatin and gemcitabine as first-line treatment. | 100% | 39566070 |
| survival | (observed in patient cohort) The median progression-free survival was 5.6 months in patients with advanced biliary tree cancer treated with durvalumab plus cisplatin and gemcitabine as first-line treatment. | 100% | 39566070 |
| survival | (clinical trial result) Durvalumab plus first-line chemotherapy (gemcitabine plus cisplatin) showed improved survival vs chemotherapy alone in the TOPAZ-1 trial. | 100% | 39566070 |
| drug efficacy | The combination of gemcitabine with cisplatin (GemCis) has been the standard of care for palliative treatment of BTC for decades. | 100% | 39560069 |
| survival | (observed in patient cohort) The median progression-free survival was 5.6 months (95%CI, 4.4-6.9) in patients with advanced biliary tree cancer treated with durvalumab plus cisplatin and gemcitabine as first-line treatment. | 100% | 39566070 |
| survival | (observed in patient cohort) The median progression-free survival was 5.6 months (95%CI, 4.4-6.9) in patients with advanced biliary tree cancer treated with durvalumab plus cisplatin and gemcitabine as first-line treatment. | 100% | 39566070 |
| drug efficacy | Durvalumab in combination with gemcitabine and cisplatin (GCD) treatment showed a survival benefit in patients with advanced biliary tract cancer (clinical trial result). | 100% | 40868170 |
| drug efficacy | (observed in patient cohort) The objective response rate was 31.1% in patients with advanced biliary tree cancer treated with durvalumab plus cisplatin and gemcitabine as first-line treatment. | 100% | 39566070 |
| survival | (observed in patient cohort) The median overall survival was 15.8 months in patients with advanced biliary tree cancer treated with durvalumab plus cisplatin and gemcitabine as first-line treatment. | 100% | 39566070 |
| survival | (observed in patient cohort) The median progression-free survival was 5.6 months (95%CI, 4.4-6.9) in patients with advanced biliary tree cancer treated with durvalumab plus cisplatin and gemcitabine as first-line treatment. | 100% | 39566070 |
| drug efficacy | Durvalumab in combination with cisplatin and gemcitabine is approved for the treatment of patients with unresectable or metastatic biliary tract cancers (BTC) (clinical trial result). | 100% | 38856639 |
| survival | (clinical trial result) Durvalumab plus first-line chemotherapy (gemcitabine plus cisplatin) showed improved survival vs chemotherapy alone in the TOPAZ-1 trial. | 100% | 39566070 |
| survival | (observed in patient cohort) Responders to durvalumab plus cisplatin and gemcitabine had significantly longer survival than non-responders (15.8 vs 3.3 months). | 100% | 39566070 |
| survival | (observed in patient cohort) The median progression-free survival was 5.6 months (95%CI, 4.4-6.9) in patients with advanced biliary tree cancer treated with durvalumab plus cisplatin and gemcitabine as first-line treatment. | 100% | 39566070 |
| survival | (clinical trial result) The TOPAZ-1 trial demonstrated survival benefit with addition of durvalumab to gemcitabine plus cisplatin compared to chemotherapy alone. | 100% | 38774819 |
| drug efficacy | (observed in patient cohort) Among the 45 patients with advanced biliary tree cancer treated with durvalumab plus cisplatin and gemcitabine as first-line treatment, an additional 40% (18 patients) had stable disease. | 100% | 39566070 |
| survival | (observed in patient cohort) The median progression-free survival was 5.6 months in patients with advanced biliary tree cancer treated with durvalumab plus cisplatin and gemcitabine as first-line treatment. | 100% | 39566070 |
| drug efficacy | (observed in patient cohort) The objective response rate was 31.1% among 45 patients with advanced biliary tree cancer treated with durvalumab plus cisplatin and gemcitabine as first-line treatment. | 100% | 39566070 |
| survival | (clinical trial result) The TOPAZ-1 trial demonstrated survival benefit with addition of durvalumab to gemcitabine plus cisplatin compared to chemotherapy alone. | 100% | 38774819 |
| drug efficacy | The combination of gemcitabine with cisplatin (GemCis) has been the standard of care for palliative treatment of BTC for decades. | 100% | 39560069 |
| survival | (observed in patient cohort) Responders to durvalumab plus cisplatin and gemcitabine had significantly longer survival than non-responders (15.8 vs 3.3 months). | 100% | 39566070 |
| survival | (clinical trial result) Durvalumab plus first-line chemotherapy (gemcitabine plus cisplatin) showed improved survival vs chemotherapy alone in the TOPAZ-1 trial. | 100% | 39566070 |
| drug efficacy | Treatment with gemcitabine+cisplatin+durvalumab(GCD) resulted in a complete response in a patient with intrahepatic cholangiocarcinoma with lymph node recurrence (clinical trial result). | 100% | 40420374 |
Off-Target Findings (0)
No Boltz-2 / Chai-1 off-target panel claims recorded for this drug.